Stephanie Krebs - 14 Feb 2025 Form 4 Insider Report for Sensei Biotherapeutics, Inc. (SNSE)

Role
Chief Business Officer
Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol
SNSE
Transactions as of
14 Feb 2025
Transactions value $
$0
Form type
4
Date filed
14 Feb 2025, 18:06
Previous filing
23 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNSE Stock Option (Right to Buy) Award $0 +120K $0.00 120K 14 Feb 2025 Common Stock 120K $0.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 14, 2026, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.